 Bio-Path Holdings Inc NASDAQ: BPTH has completed the safety run-in of Stage 2 of the Phase 2 study evaluating prexigebersen to treat acute myeloid leukemia AML in combination with frontline therapies, decitabine and venetoclax. The safety run-in comprised six evaluable patients. 